Tokai Pharmaceuticals Obtains $23,000,000 Series D Financing Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=05bcfc14-3ff6-4901-a30f-5e3b9d43f06c&Preview=1 -
Date
9/20/2011 -
Company Name
Tokai Pharmaceuticals -
Mailing Address
One Broadway 11th floor Cambridge , MA 02142 -
Company Description
The company develops biopharmaceutical products that focus on endocrine treatment. -
Website
http://www.tokaipharmaceuticals.com -
Transaction Type
Venture Equity -
Transaction Amount
$23,000,000 -
Transaction Round
Series D -
Proceeds Purposes
The new money will go toward Tokai’s lone drug in development, galeterone (TOK-001), as it advances into the second of three phases of trials normally required for FDA approval. -
M&A Terms
-
Venture Investor
Novartis Venture Fund -
Venture Investor
Apple Tree Partners -
Venture Investor
Undisclosed
